Bio-Rad Laboratories has introduced Vericheck ddPCR ™ Empty-Full Capsid Kits for AAV2 and AAV8, expanding the scope of their AAV vector characterization portfolio. These kits are a valuable resource for contract testing laboratories supporting gene therapy development.
AAV2 dominates clinical trials, while AAV8 is crucial for liver-directed therapies. With the addition of these ddPCR kits to the existing AAV5 and AAV9 options, Bio-Rad provides solutions for roughly 70% of the AAV gene therapy market. The kits enable absolute quantification of capsid titer, genome titer, and full-to-empty capsid ratios, offering unmatched accuracy.
Benefits for Contract Testing Labs
- Expanded Offerings: Service a broader range of gene therapy clients with support for AAV2, AAV5, AAV8, and AAV9.
- Regulatory Alignment: Ensure compliance with industry guidelines for CQA analysis.
- Cost-Effective: Perform detailed analyses with minimal sample input.
- Reproducibility: Guarantee reliable results across both crude and purified samples.
- Industry-Leading Technology: Leverage the precision of Droplet Digital™ PCR Systems for superior data quality.
With Bio-Rad’s Vericheck ddPCR™ kits, contract labs can confidently provide high-quality AAV testing services to accelerate the development of innovative gene therapies.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: “Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization“
